Martinez-Picado J - Search Results

1

HIV integrase inhibitors in ART-experienced patients.

Blanco JL, Martinez-Picado J. Blanco JL, et al. Curr Opin HIV AIDS. 2012 Sep;7(5):415-21. doi: 10.1097/COH.0b013e328356dcb6. Curr Opin HIV AIDS. 2012. PMID: 22871635 Review.

2

Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.

Clotet B, Ruiz L, Martinez-Picado J, Negredo E, Hill A, Popescu M. Clotet B, et al. HIV Clin Trials. 2002 Jul-Aug;3(4):316-23. doi: 10.1310/67te-gpxq-r1lb-bpkg. HIV Clin Trials. 2002. PMID: 12187506

3

Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.

Buzón MJ, Marfil S, Puertas MC, Garcia E, Clotet B, Ruiz L, Blanco J, Martinez-Picado J, Cabrera C. Buzón MJ, et al. Antivir Ther. 2008;13(7):881-93. Antivir Ther. 2008. PMID: 19043922

4

[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].

Llibre JM, Martínez-Picado J. Llibre JM, et al. Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:17-22. doi: 10.1016/s0213-005x(08)76568-6. Enferm Infecc Microbiol Clin. 2008. PMID: 19572421 Review. Spanish.

5

The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.

Buzón MJ, Dalmau J, Puertas MC, Puig J, Clotet B, Martinez-Picado J. Buzón MJ, et al. AIDS. 2010 Jan 2;24(1):17-25. doi: 10.1097/QAD.0b013e328331c81e. AIDS. 2010. PMID: 19770695

6

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.

Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Pérez-Elías MJ, Aguilera A, Caballero E, Soriano V, de Mendoza C; Resistance Platform of the Spanish AIDS Research Network. Anta L, et al. AIDS. 2013 Jan 2;27(1):81-5. doi: 10.1097/QAD.0b013e3283584500. AIDS. 2013. PMID: 22842995

7

Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.

Anta L, Blanco JL, Llibre JM, García F, Pérez-Elías MJ, Aguilera A, Pérez-Romero P, Caballero E, Vidal C, Cañizares A, Gutiérrez F, Dalmau D, Iribarren JA, Soriano V, de Mendoza C; Drug Resistance Platform of the Spanish AIDS Research Network. Anta L, et al. J Antimicrob Chemother. 2013 Sep;68(9):1994-2002. doi: 10.1093/jac/dkt146. Epub 2013 Apr 29. J Antimicrob Chemother. 2013. PMID: 23629015

8

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.

Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J; MaraviBoost Collaborative Group. Puertas MC, et al. AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066. AIDS. 2014. PMID: 24185044 Clinical Trial.

9

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.

Doyle T, Dunn DT, Ceccherini-Silberstein F, De Mendoza C, Garcia F, Smit E, Fearnhill E, Marcelin AG, Martinez-Picado J, Kaiser R, Geretti AM; CORONET Study Group. Doyle T, et al. J Antimicrob Chemother. 2015 Nov;70(11):3080-6. doi: 10.1093/jac/dkv243. Epub 2015 Aug 26. J Antimicrob Chemother. 2015. PMID: 26311843 Free PMC article.

10

Persistent HIV-1 replication during antiretroviral therapy.

Martinez-Picado J, Deeks SG. Martinez-Picado J, et al. Curr Opin HIV AIDS. 2016 Jul;11(4):417-23. doi: 10.1097/COH.0000000000000287. Curr Opin HIV AIDS. 2016. PMID: 27078619 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

266 results

Search Page